Every material Form 8-K IRONWOOD PHARMACEUTICALS INC has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ironwood Pharmaceuticals reported third quarter 2026 total revenue of $133.0 million and GAAP net income of $59.8 million, up from $122.1 million and $40.1 million a year earlier. The company raised full-year 2026 guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA for the second consecutive quarter, and announced that Chief Commercial Officer Tammi Gaskins will become CEO on January 1, 2027.
Q3 2026 LINZESS U.S. net sales were $324.9 million, up 3.2% from $314.9 million a year earlier, with demand up 4.9%.
Updated 2026 guidance: LINZESS U.S. net sales $1.20 - $1.25 billion, total revenue $485 - $510 million, adjusted EBITDA greater than $350 million.
Quarter-end cash and cash equivalents were $86.4 million, and the revolving credit facility balance was reduced by $60.0 million to $325.0 million.
Tammi Gaskins will succeed Tom McCourt as CEO effective January 1, 2027; McCourt will remain on the Board.
Ironwood Pharmaceuticals reported second quarter 2026 total revenue of $113.0 million, up from $85.2 million a year earlier, and GAAP net income of $51.3 million, or $0.31 per diluted share, compared with $0.14 a year earlier. The company raised its full-year 2026 guidance for U.S. LINZESS net sales, total revenue and adjusted EBITDA, and repaid a $200 million convertible note at maturity from cash on hand.
Q2 2026 U.S. LINZESS net sales were $282.3 million, up 14% from $248.0 million in Q2 2025
Updated 2026 guidance: U.S. LINZESS net sales $1.15 to $1.20 billion (prior $1.125 to $1.175 billion); total revenue $460 to $485 million; adjusted EBITDA greater than $310 million
Cash and cash equivalents were $79.1 million at June 30, 2026, down from $215.5 million at end of 2025; $385.0 million drawn on the revolving credit facility
Ronald Silver serves as Interim CFO after Gregory Martini's resignation in May 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IRONWOOD PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →